WA-SORACOM
20.7.2022 14:03:48 CEST | Business Wire | Press release
Soracom , Inc., a global provider of advanced IoT connectivity, today announced a partnership with IDEMIA, a leading company in identity technologies, to offer innovative SMBs, SMEs and enterprises in North America and Europe expanded embedded universal integrated circuit card (eUICC) capabilities based on IDEMIA's IoT-optimized DAKOTA SMART eSIM technology. The offering is the first deployment of DAKOTA SMART in the United States.
This GSMA-certified eSIM is designed to specifically meet the needs of IoT devices, even low-cost devices with highly constrained memory, power and processing capability. IDEMIA’s eSIM technology features advanced low-power capabilities, including Suspend, Resume, and eDRX, making it more power efficient for LTE-M/NB-IoT services while supporting all cellular standards from 2G to 5G where available. It is available in standard MFF2 (5x6mm), ultra-compact plug-in card (2x2mm), and chip scale package (CSP) form factors with commercial- and industrial-grade versions available.
The cloud-native Soracom platform is also intended specifically for the needs of the companies and teams building new experiences around connected devices. Soracom's global connectivity and industry-leading network management tools help to reduce total cost of ownership, accelerate speed to market, and ensure complete control over every connection in a customer's IoT fleet.
In addition to the GSMA standard Remote SIM Provisioning capability, DAKOTA SMART is compatible with Soracom's Subscription Containers multi-IMSI solution, which extends profile management capabilities to any Soracom SIM or eSIM connected with Soracom’s standard global data plan. This allows profile-swapping where multiple profiles are available without interrupting access to Soracom platform services.
“Many potential IoT applications have strict requirements in terms of highly constrained memory, power and processing capabilities,” said Kenta Yasukawa, cofounder and CTO at Soracom. “Together, Soracom and IDEMIA are removing these barriers to entry, making it simple for companies to build new, leading-edge IoT experiences for their customers around the world.”
“The ever-evolving world of IoT demands and drives innovation to help bring this connected world to life. We are delighted to be part of the Soracom journey as they expand their global reach and technology evolution. Utilizing our flagship eSIM solution, with its full range of connectivity options, form factors and dedicated IoT features, together we will enable new innovative solutions in this diverse ecosystem,” said Jason Rousseau-Hall, Business Director for IoT M2M, Connectivity Services, IDEMIA.
For more information on opportunities to deploy IDEMIA DAKOTA SMART eSIM solutions on the Soracom platform, visit www.soracom.io .
About IDEMIA
As leader in identity technologies, IDEMIA is on a mission to unlock the world and make it safer. Backed by cutting-edge R&D, IDEMIA provides unique technologies, underpinned by long-standing expertise in biometrics, cryptography, data analytics, systems and smart devices. IDEMIA offers its public and private customers payment, connectivity, access control, travel, identity and public security solutions. Every day, around the world, IDEMIA secures billions of interactions in the physical and digital worlds.
With nearly 15,000 employees, IDEMIA is trusted by over 600 governmental organizations and more than 2,300 enterprises spread over 180 countries, with an impactful, ethical and socially responsible approach.
For more information, visit www.idemia.com and follow @IDEMIAGroup on Twitter.
About Soracom
Soracom is leading the democratization of IoT connectivity, offering robust solutions specifically designed to make it easy to build, operate, and scale IoT deployments. Founded in 2015, Soracom now serves more than 20,000 startups, SMBs and global enterprises across all industries, from agriculture, energy, construction and transportation to consumer electronics, manufacturing, real estate and healthcare. Customers trust Soracom for affordable, reliable connectivity that accelerates speed to market, makes it easy to connect to the cloud, and offers access to a worldwide partner ecosystem. More information is available at www.soracom.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220720005275/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom